Vertex Pharmaceuticals Shares Outstanding

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

Vertex Pharmaceuticals shares-outstanding fundamental analysis lookup allows you to check this and other indicators for Vertex Pharmaceuticals Incorpor or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools
Symbol
Refresh

Vertex Pharmaceuticals Shares Outstanding Analysis

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted bases which include exotic instruments such as options, or convertibles bonds.
 2017 2018 2019 2020 (projected)
Receivables310.25 M414.87 M373.38 M402.86 M
Inventories111.83 M124.36 M111.92 M120.76 M
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKOSYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase III clinical trial VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain CTX001 that is in Phase III clinical trial for the treatment of beta-thalassemia and sickle cell diseases and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG Arbor Biotechnologies, Inc. Moderna Therapeutics, Inc. Genomics plc Merck KGaA Darmstadt, Germany X-Chem, Inc. Janssen Pharmaceuticals, Inc. Merck KGaA Kymera Therapeutics Ribometrix, Inc. and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
ReceivablesInventories
Shares Outstanding 
 = 
Public Shares 
Repurchased 
More About Shares Outstanding | All Equity Analysis
Vertex Pharmaceuticals Shares Outstanding  =
257.15 M
ValuationFundamentalsBuy or Sell

Vertex Pharmaceuticals Shares Outstanding Over Time Pattern

 Vertex Pharmaceuticals Weighted Average Shares 
    
  Timeline 

About Shares Outstanding

Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Compare to competition
Accumulated Other Comprehensive Income
Based on latest financial disclosure Vertex Pharmaceuticals Incorpor has 257.15 M of shares currently outstending. This is 42.44% higher than that of the Healthcare sector, and 140.65% higher than that of Biotechnology industry, The Shares Outstanding for all stocks is 55.03% higher than the company.

Vertex Pharmaceuticals Shares Outstanding Peer Comparison

  Shares Outstanding 
    
  Vertex Pharmaceuticals Comparables 
Vertex Pharmaceuticals is rated below average in shares outstanding category among related companies.

Vertex Pharmaceuticals current financial ratios